Durvalumab (Imfinzi®) is indicated for the treatment of locally advanced, unresectable non-small cell lung cancer (NSCLC) in adults whose tumours express PD-L1 ≥1% on tumour cells and whose disease has not progressed following platinum-based chemo-radiation therapy (CRT).
| NCPE Assessment Process | Ongoing |
| Rapid review commissioned | 29/03/2019 |
| Rapid review completed | 29/04/2019 |
| Rapid Review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of durvalumab compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 01/05/2019 |
| Pre-submission consultation with Applicant | 10/06/2019 |
| Submission received from Applicant | 30/08/2019 |
| Preliminary review sent to Applicant | 20/12/2019 |
| NCPE assessment re-commenced | 30/01/2020 |
| Factual accuracy sent to Applicant | 16/04/2020 |
| NCPE assessment re-commenced | 24/04/2020 |
| NCPE assessment completed | 07/05/2020 |
| NCPE assessment outcome | The NCPE recommends that durvalumab be considered for reimbursement if cost effectiveness can be improved relative to existing treatments.* |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.